2023年7月24日 · Overall survival (OS) benefits of neoadjuvant immunotherapy remain elusive in locally advanced esophageal squamous cell carcinomas (ESCC). Here, we reported the results of a phase 1b trial of...

2024年12月2日 · 最近，免疫检查点抑制剂（ICI）显示出治疗效果，其单药疗法或联合疗法已获批用于晚期食管 SCC（ESCC）。 PD-L1 表达是 ESCC 一线 ICIs 治疗的唯一临床适用生物标志物，但对 ICIs 的反应存在差异，新的预测性生物标志物正在探索中。 此外，新型抗体-药物偶联物（ADC）有望用于晚期 ESCC。 本文概述了晚期 ESCC 潜在靶向和免疫治疗的现状和未来前景。 研究背景. ESCC的分子特征. ESCC1 在亚洲患者中常见，其特征是 NRF2 通路改变此外，存 …

2024年12月1日 · The KEYNOTE-181 trial, a phase 3 trial comparing pembrolizumab monotherapy versus standard chemotherapy with taxane or irinotecan as a second-line treatment for advanced ESCC and esophageal adenocarcinoma, demonstrated prolonged OS in overall population with the enriched benefit in patients with PD …

5 天之前 · Better OS and DFS were obtained for the NCIT group than for the NCRT group, regardless of whether adjuvant immunotherapy was given. Conclusions and relevance: Compared with NCRT, patients with locally advanced ESCC receiving NCIT had better 2-year OS and DFS. The decrease in distant metastasis may be the main reason, but further prospective ...

Overall survival (OS) benefits of neoadjuvant immunotherapy remain elusive in locally advanced esophageal squamous cell carcinomas (ESCC). Here, we reported the results of a phase 1b trial of neoadjuvant PD-L1 blockade with adebrelimab in resectable ESCC. Patients received two neoadjuvant doses of a …

2025年1月31日 · The present study aimed to develop a nomogram model for predicting overall survival (OS) in esophageal squamous cell carcinoma (ESCC) patients. A total of 205 patients with ESCC were enrolled and randomly divided into a training cohort (n = 153) and a test cohort (n = 52) at a ratio of 7:3.

2025年3月4日 · These results represent an unprecedented improvement in OS in first-line ESCC patients. “Today’s approval, our third from the FDA in less than a year, reflects our dedication to advancing innovative therapies and addressing critical needs in cancer care,” said Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeiGene ...

2 天之前 · In the phase 2 EPOCI1802 trial, atezolizumab monotherapy elicited a cCR rate of 42.1%, an ORR of 65.8%, and a 12-month OS rate of 65.8% in advanced ESCC.

2025年3月17日 · This study aimed to evaluate the predictive value of preoperative radiomics and the prognostic nutritional index for individuals with ESCC and to develop a comprehensive model for estimating postoperative overall survival (OS) in these patients. A retrospective analysis was conducted on 466 patients with ESCC from two medical centers.

2024年6月19日 · ESCORT-1ˢᵗ研究是全球首个探索免疫治疗（卡瑞利珠单抗）联合TP（紫杉醇+顺铂）方案一线治疗晚期转移性食管鳞癌的Ⅲ期临床研究。 基于ESCORT-1ˢᵗ研究结果，卡瑞利珠单抗成为我国晚期食管鳞癌一线标准治疗药物。